Keywords
Aspiration, bronchiole, bronchiolitis, diacetyl, DIPNECH, inhalational injury, small airways, smoking, vaping, virus
Aspiration, bronchiole, bronchiolitis, diacetyl, DIPNECH, inhalational injury, small airways, smoking, vaping, virus
“Bronchiolitis” is a term used to designate injury to the bronchioles (small airways with a diameter of 2 mm or less) resulting in inflammation and/or fibrosis1. Many different forms of bronchiolitis have been described over the years, and there is no consensus in classifying these subtypes. Bronchiolitis described in infants and children is a form of acute bronchiolitis representing an infectious process, commonly resulting in respiratory distress and wheezing2. It is caused by a viral infection, most commonly respiratory syncytial virus. In adults, however, a heterogeneous spectrum of bronchiolar disorders is encountered and is more often caused by chronic disease processes1,3–6. Etiology, clinical features, radiologic findings, treatment strategies, and prognostic implications vary among these disorders. Thus, it is crucial to distinguish the subtypes of bronchiolitis to optimize management and outcomes.
In this review, current concepts regarding bronchiolitis in adults with an emphasis on recent advances will be described. The forms of bronchiolitis described herein should not be confused with “bronchiolitis obliterans organizing pneumonia” or BOOP (the currently preferred term is “organizing pneumonia” [OP]), which manifests as parenchymal lung disease rather than strictly bronchiolar disease.
In approaching a heterogeneous entity such as bronchiolitis in adults, a classification scheme is useful in organizing our concepts and facilitating our understanding. Such classification needs to be based on some discriminatory parameter3,7,8. It may seem rational to classify bronchiolitis by etiology. However, the underlying cause is often not apparent on clinical presentation. In clinical practice, the task is to recognize the presenting respiratory illness as a form of bronchiolitis, then to identify the underlying cause.
Perhaps the most useful framework in the clinical approach to patients with suspected bronchiolitis is a classification based on underlying histopathologic patterns (Table 1), which, in large measure, correlate with the clinical and radiologic presentation and help narrow the list of potential causes to be considered3. Ultimately, the treatment of bronchiolitis should be aimed at the cause (e.g. cessation of exposure to offending inhalant) of the disease whenever possible, although it is not always identifiable.
It should be noted that bronchiolitis can be encountered histopathologically or radiologically as a component of interstitial lung diseases (involving predominantly the lung parenchyma), e.g. hypersensitivity pneumonitis, and large airway diseases such as bronchiectasis1. This issue is exemplified by a disease entity formerly called BOOP, which was characterized by the histologic presence of organizing connective tissue in lumens of small airways, alveolar ducts, and alveoli9. It is generally associated with clinico-radiologic features of parenchymal lung disease including restrictive pulmonary impairment and parenchymal opacities. Thus, this histopathologic entity was later renamed simply “organizing pneumonia” and represents a non-specific pattern of lung injury seen in many diverse clinical contexts, including infectious and non-infectious processes1,10. In the absence of an identifiable cause, it is referred to as “cryptogenic OP” (COP) and currently classified as a form of idiopathic interstitial pneumonia11. This review, however, focuses on respiratory diseases that manifest predominantly in the bronchioles (“primary bronchiolitis”).
Respiratory bronchiolitis (RB) is likely the most common form of bronchiolitis and is usually related to cigarette smoking12. It is characterized by the histologic presence of tan-pigmented macrophages in the respiratory bronchioles11. The presence of RB may not be associated with respiratory symptoms. Radiologically, RB manifests with centrilobular micronodules, which is often how the presence of this disease process is identified4,7,13.
Histopathologic lesion of RB is commonly seen in the lung specimens from smokers who are diagnosed with other smoking-related pulmonary diseases including bronchogenic carcinoma and pulmonary Langerhans’ cell histiocytosis, a form of smoking-related interstitial lung disease14,15. When RB is associated with evidence of interstitial lung disease including diffuse pulmonary infiltrates (typically patchy ground-glass opacities on high-resolution chest CT scan) and pulmonary function impairment, the disease process is referred to as RB-associated interstitial lung disease (RB-ILD)16,17.
In recent years, RB has been diagnosed on the basis of clinical context (smoking history) and typical chest CT findings (centrilobular ground-glass nodules) without histopathologic confirmation when other potential explanations for the presenting clinico-radiologic features are absent7,13. Often, these patients have no respiratory symptoms other than a smoker’s cough.
The management focuses on smoking cessation, since RB is related to cigarette smoking in most cases13,17. Continued smoking may lead some patients to develop evidence of interstitial lung disease including RB-ILD.
In the current era of CT screening for lung cancer, there has been increasing interest in interstitial lung abnormalities (ILAs) encountered in up to 10% of asymptomatic study participants18. The presence of ILAs is associated with increasing age and smoking history18,19. Diffuse centrilobular nodularity, as can be seen in RB, is a component of these ILAs and is distinguished from “fibrotic” ILAs (reticulation, traction bronchiectasis, and honeycombing)18,19.
Acute bronchiolitis is a histopathologic pattern of injury underlying the illness referred to as “bronchiolitis” in infants and young children1,2,20. It usually represents a viral lower respiratory tract infection, most commonly caused by respiratory syncytial virus2,21. Histopathology of acute bronchiolitis is characterized by intense acute inflammation of bronchioles with epithelial necrosis and sloughing, along with submucosal edema and peribronchiolar infiltration1,22.
In adults, viral respiratory tract infections usually present as tracheobronchitis or pneumonia. However, some adults may experience acute bronchiolitis as the dominant form of viral illness. Various viruses have been associated with acute bronchiolitis in adults and include respiratory syncytial virus, adenovirus, influenza, and parainfluenza23–27. Non-viral infections including Mycoplasma pneumoniae, Streptococcus pneumoniae, and Haemophilus influenzae as well as acute toxic inhalational injury can also induce acute bronchiolitis23,26–28. On chest CT scanning, these patients manifest centrilobular nodules and multifocal tree-in-bud opacities (Figure 1) rather than bronchial wall thickening (bronchitis) or consolidative/ground-glass opacities (pneumonia)1,23,24,26,27. The management of acute bronchiolitis in adults is aimed at the underlying cause along with supportive measures which may include mechanical ventilation in severe cases.
Constrictive bronchiolitis, also referred to as obliterative bronchiolitis, has many causes and is encountered in various clinical contexts. For example, it is recognized as a form of airway disease associated with autoimmune diseases such as rheumatoid arthritis and Sjögren’s syndrome. Constrictive bronchiolitis underlies “bronchiolitis obliterans syndrome” (BOS; see below), a common form of chronic lung allograft rejection presenting as obstructive lung disease. Constrictive bronchiolitis can also be seen as a late sequela of viral lower respiratory tract infections (Swyer–James–MacLeod syndrome) or toxic inhalational injuries1,29–33. Other causes of constrictive bronchiolitis include drugs, inflammatory bowel disease, and paraneoplastic pemphigus1,34,35. Constrictive bronchiolitis is a rare form of drug-induced lung disease, but the list of drugs implicated in causing this form of lung injury has been expanding in recent years and include penicillamine, gold, 5-fluorouracil, crack cocaine, afatinib, mesalamine, rituximab, and immune checkpoint inhibitors1,36–40. In the absence of an identifiable cause, the term “cryptogenic constrictive bronchiolitis” is used1,31.
Histologically, constrictive bronchiolitis is characterized by bronchiolar inflammation and peribronchiolar fibrosis that encroaches on the bronchiolar lumen. This constrictive process may result in complete obliteration of the airway lumen1,6.
Bronchiolitis obliterans refers to a form of constrictive bronchiolitis seen in transplant recipients, predominantly lung or hematopoietic cell transplant34,41–43. BOS in lung transplant recipients is defined as a persistent decrease in forced expiratory volume in one second (FEV1) attributable to chronic lung allograft dysfunction and not caused by other identifiable causes44. In BOS, pulmonary function impairment manifests evidence of airflow obstruction and needs to be distinguished from “restrictive allograft syndrome”, which is a restrictive phenotype of chronic lung allograft dysfunction as recently proposed in a consensus statement by the International Society of Heart and Lung Transplantation45.
There have been increasing reports in recent years regarding diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). DIPNECH is an under-recognized respiratory disease characterized by the proliferation of neuroendocrine cells in the airway walls46,47. It is encountered predominantly in middle-aged women. Radiologically, it is characterized by mosaic attenuation with multiple small nodules (Figure 2), a combination that is highly suggestive of this disease48. DIPNECH has been classified as a preinvasive lesion in the category of neuroendocrine tumors in the 2015 World Health Organization (WHO) classification of lung tumors49.
Some patients with DIPNECH may be asymptomatic and identified on the basis of abnormal chest CT findings, whereas the clinical course in other patients is characterized by the development of carcinoid tumors or progressive airflow obstruction. The latter situation represents constrictive bronchiolitis associated with DIPNECH (termed “DIPNECH syndrome”) and is thought to be mediated by peptides secreted by hyperplastic neuroendocrine cells leading to peribronchiolar fibrosis and progressive narrowing of the small airways46,47,50. A definitive diagnosis requires histopathologic confirmation, usually surgical lung biopsy. For patients with DIPNECH syndrome and progressive obstructive lung impairment, various therapeutic options have been tried including oral and inhaled glucocorticoids, cytotoxic agents, and somatostatin analogues, but an optimal/effective treatment has not been identified46,47,51. A recent report described three patients with DIPNECH syndrome who experienced improvement with sirolimus (an inhibitor of mechanistic target of rapamycin [mTOR] pathway) therapy52. In most patients, DIPNECH is associated with an indolent course, but progressive respiratory insufficiency necessitating lung transplantation has been reported. Pulmonary neuroendocrine tumorlets (neuroendocrine cell hyperplasia less than 5 mm in size) are commonly seen in patients with DIPNECH who are also at risk for carcinoid tumors46,53.
In recent years, several inhalational causes of constrictive bronchiolitis have been described. These have included inhalational exposures associated with military service in Southwest Asia and Afghanistan and the use of flavoring chemicals in the food industry28,54,55. Diacetyl was identified as the chemical responsible for constrictive bronchiolitis occurring in workers in microwave popcorn manufacturing56. Similar respiratory illnesses associated with exposure to diacetyl and 2,3-pentanediol have been identified in workers in other food production settings, including cookie production and coffee-processing facilities28,57. It seems likely that other environmental and occupational exposures will be implicated in the development of constrictive bronchiolitis and account for some non-smokers diagnosed with chronic obstructive pulmonary disease (COPD)58,59.
Follicular bronchiolitis is characterized histologically by non-neoplastic lymphoid hyperplasia of the bronchus-associated lymphoid tissue1,6. Imaging features on high-resolution CT of the chest are bilateral presence of small centrilobular nodules and patchy ground-glass opacities1,4,60. Follicular bronchiolitis is usually encountered in patients with connective tissue diseases (e.g. rheumatoid arthritis and Sjögren syndrome) and immunodeficiency disorders1,60,61. In some cases, an underlying cause may not be identifiable.
Recently, a novel familial form of autoimmune disorder associated with follicular bronchiolitis was described. COPA syndrome is a rare disease caused by heterozygous missense mutations in the gene encoding coatomer subunit alpha (COPA)62–64. This monogenic disorder is inherited in an autosomal-dominant manner with variable expressivity. The coatomer protein complex plays a role in intracellular vesicle trafficking, and impaired protein transport is thought to result in abnormal cellular autophagy and immune dysregulation62,63. Affected family members manifest arthritis, circulating autoimmune antibodies (particularly rheumatoid factor), follicular bronchiolitis, and recurrent respiratory infections64–66. Diffuse alveolar hemorrhage may occur in about one-half of patients65. Chest CT scan demonstrates diffuse small lung nodules often associated with small cysts64,66. These patients tend to experience gradual progression of their lung disease despite treatment with glucocorticoids and other immunomodulator therapy; some have undergone lung transplantation65.
Diffuse aspiration bronchiolitis is a form of aspiration-related lung disease resulting from chronic recurrent aspiration, which is often occult67–72. This disease presents with an insidious onset of cough that persists, sometimes accompanied by exertional dyspnea, and bilateral pulmonary infiltrates that may be mistaken for interstitial lung disease. Although risk factors for aspiration such as gastroesophageal reflux disease and sedative medication use are commonly present in these patients, the diagnosis is frequently unsuspected until foreign bodies representing food particles are identified on lung biopsy67,70–72.
In contrast to other more recognized forms of aspiration-related lung diseases such as aspiration pneumonia and aspiration pneumonitis, radiologic findings associated with diffuse aspiration bronchiolitis on CT consist of centrilobular nodules and tree-in-bud opacities67,68,71,73.
The management of diffuse aspiration bronchiolitis is aimed at the underlying risk factors for aspiration such as gastroesophageal reflux disease, the use of sedating medications, and neuromuscular disorders72.
Although the classification scheme depicted in Table 1 includes most forms of bronchiolitis encountered in clinical practice, new forms of bronchiolitis continue to be discovered. A unique histopathologic pattern of lymphocytic bronchiolitis and alveolar ductitis with emphysema was recently described in five never-smokers employed at a manufacturing facility for industrial machines74. These patients manifested evidence of airflow obstruction, impaired gas exchange, and centrilobular emphysema. No cause has yet been identified for this previously unrecognized occupational lung disease.
Recently, there has been a multistate outbreak of respiratory illnesses associated with the use of electronic cigarettes (e-cigarettes) or vaping75. The exact chemical or chemicals responsible for this illness have not yet been identified. Lung biopsy obtained in these patients has revealed patterns of acute lung injury including diffuse alveolar damage or fibrinous OP with a bronchiolocentric distribution and accompanied by bronchiolitis76. RB-ILD and acute eosinophilic pneumonia have also been reported to occur with e-cigarette use77–79.
Bronchiolitis is encountered commonly, sometimes as a relatively minor component of the disease process that mainly affects the lung parenchyma or large airways but at other times may be the principal site of the lung injury (primary bronchiolitis). In adults, the spectrum of bronchiolar injury is broad in terms of the histopathologic pattern and causes. Accordingly, imaging features on chest CT as well as pulmonary function findings will vary among different forms of bronchiolitis. Correlation of the clinical context with CT and pulmonary function findings may enable a working diagnosis in some patients, while lung biopsy may be needed for diagnostic clarification in others. Identification of the type of bronchiolitis and the underlying cause, whenever possible, optimizes management and outcomes.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 08 Jun 20 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)